Oxygen chamber therapy put to the test for dozens of diseases

NCT ID NCT07240649

Not yet recruiting Disease control Sponsor: Jay C. Buckey Jr. Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jul 07, 2026 · Updated 3 times

Summary

This study will test hyperbaric oxygen therapy (HBOT) — breathing pure oxygen in a pressurized chamber — for over 30 conditions, including long COVID, Crohn's disease, frostbite, and multiple sclerosis. Researchers will track 100 patients to see if HBOT improves their quality of life. The goal is to gather data to support wider use of this treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: hyperbaric oxygen therapy (breathing pure oxygen in a pressurized chamber)
What this could lead to: If it works, this could expand the use of hyperbaric oxygen therapy to many more conditions, offering a new treatment option for patients who have few alternatives.
What could go wrong: This is an early registry study, not a controlled trial, so results may not prove cause and effect. Many conditions are being tested at once, so benefits may vary widely. Risks include ear/sinus pain and, rarely, lung injury.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE COVID-19 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute intestinal ischemia anterior ischemic optic neuropathy avascular necrosis branch retinal artery occlusion calciphylaxis central retinal vein occlusion chronic cystitis Clostridium difficile colitis Craniocerebral Trauma Crohn disease decubitus ulcer epidermolysis bullosa frostbite graft versus host disease head injury hypospadias inclusion body myositis Invasive Fungal Infections ligament disorder malignant otitis externa multiple sclerosis nervous system injury non-arteritic anterior ischemic optic neuropathy osteonecrosis pneumatosis cystoides intestinalis post-COVID-19 disorder pouchitis prosthesis-related infectious disease pterygium pyoderma gangrenosum Raynaud disease Rectovaginal Fistula retinal artery occlusion retinal vein occlusion systemic mycosis tinnitus ulcerative colitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE COVID-19 ANASTOMOSIS, LEAKING AVASCULAR NECROSIS OF BONE AXONOTMESIS BRANCH RETINAL ARTERY OCCLUSION CALCIPHYLAXIS CARTILAGE INJURY CENTRAL RETINAL VEIN OCCLUSION CHRONIC ANAL FISSURE CLOSTRIDIUM ENTEROCOLITIS CROHN DISEASE CYSTITIS CHRONIC DECUBITUS ULCER EPIDERMOLYSIS BULLOSA (EB) FACIAL FILLER INJECTIONS FEMORAL HEAD NECROSIS FROSTBITE GRAFT VS HOST DISEASE GREATER TROCHANTERIC PAIN SYNDROME HEAD TRAUMA HYPOSPADIAS INCLUSION BODY MYOSITIS INVASIVE FUNGAL INFECTION ISCHEMIC BOWEL LIGAMENT INJURY MALIGNANT OTITIS EXTERNA MULTIPLE SCLEROSIS NONARTERITIC ANTERIOR ISCHEMIC OPTIC NEUROPATHY OSTEONECROSIS PNEUMATOSIS INTESTINALIS POST COVID-19 CONDITION POUCHITIS PROSTHESIS RELATED INFECTIONS PTERYGIUM PYODERMA GANGRENOSUM RAYNAUD SYNDROME RECTOVAGINAL FISTULA TINNITUS ULCER ISCHEMIC ULCERATIVE COLITIS VASCULITIC ULCER

More trials for these conditions

Other studies related to the condition(s) this trial covers.